Tranylcypromine in social phobia.
Thirty-two patients meeting DSM-III criteria for social phobia entered a 1-year drug treatment with tranylcypromine in dosages between 40 and 60 mg/day. After exclusion of the early dropouts, improvement was rated as marked and moderate in 62% and 17% of the sample (N = 29), respectively. Alcohol abuse was associated with a poor outcome. Side effects were frequent and in some cases delayed the attainment of efficacious dosages until the third month of treatment. No serious adverse reactions occurred. The findings, relative to efficacy, are in accordance with a previous trial with phenelzine but need confirmation in double blind controlled studies.
Versiani
M
M
Department of Psychiatry, Federal University of Rio de Janeiro, Brazil.
Mundim
F D
FD
Nardi
A E
AE
Liebowitz
M R
MR
D000293:Adolescent; D000328:Adult; D001007:Anxiety / Q000188:drug therapy / Q000523:psychology; D001960:Bromazepam / Q000627:therapeutic use; D002997:Clomipramine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology; D014191:Tranylcypromine / Q000009:adverse effects / Q000627:therapeutic use*
D014191:Tranylcypromine; D002997:Clomipramine; D001960:Bromazepam